Natera Showcases AI and ctDNA Breakthroughs at AACR 2026
Event summary
- 20 abstracts, including two oral presentations, feature Natera’s oncology platform at AACR 2026.
- AI model achieves AUROC of 0.98 for MSI-status prediction in colorectal cancer from H&E images.
- ctDNA clearance dynamics in MSI-H metastatic CRC show 3-year OS of 96% for Signatera-negative patients.
- Latitude™ tissue-free MRD assay launching commercially in additional histologies later this year.
The big picture
Natera’s AACR presentations underscore the growing convergence of AI, real-world evidence, and liquid biopsy technologies in oncology. The company is positioning itself as a key player in data-driven cancer care, with potential to disrupt traditional tissue-based diagnostics. Success will hinge on commercializing these innovations while maintaining clinical utility across diverse tumor types.
What we're watching
- AI Integration
- How Natera’s AI-enabled genomic insights will scale across tumor types and impact pathology workflows.
- Regulatory Pathways
- Whether the PROCEED trial data will accelerate commercial adoption of blood-based screening assays.
- Competitive Positioning
- The pace at which Natera can expand Latitude™ into new histologies and maintain leadership in MRD testing.
Related topics